Related Experiment Video
Updated: Jul 16, 2025
00:26
Perspectives on Neuroscience
Published on: July 31, 2007
5.0K
Neurodegenerative Diseases: New Hopes and Perspectives.
Mohammad Aadil Bhat1, Suneela Dhaneshwar2
1Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Noida, UP, India.
Current Molecular Medicine
|September 11, 2023
Summary
Neurodegenerative diseases like Alzheimer's and Parkinson's are progressive and incurable. This review summarizes recent therapeutic advances and their current management status for these challenging conditions.
Area of Science:
- Neurology
- Neuroscience
- Pharmacology
Background:
- Neurodegenerative diseases, including Alzheimer's, Parkinson's, ALS, Huntington's, and Friedrich ataxia, are characterized by progressive neuronal loss.
- These conditions affect a growing aging global population, yet therapeutic advancements remain limited.
- There is a critical need for novel drug development to combat these debilitating diseases.
Conclusions:
- Recent research shows a promising shift towards discovering novel therapeutic agents for neurodegenerative disorders.
- The review provides a consolidated view of the current status and future directions in managing these progressive diseases.
- Continued research and development are crucial for improving patient outcomes.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
01:26Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
01:24Parkinson's Disease: Treatment
295
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
295
01:15Parkinson's Disease: Overview
592
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
592
01:15Neurogenesis and Regeneration of Nervous Tissue
856
In the CNS, neurogenesis, the birth of new neurons from stem cells, is limited to the hippocampus in adults. In other regions of the brain and spinal cord, neurogenesis is almost non-existent due to inhibitory influences from neuroglia, especially oligodendrocytes, and the absence of growth-stimulating cues. The myelin produced by oligodendrocytes in the CNS inhibits neuronal regeneration. Furthermore, astrocytes proliferate rapidly after neuronal damage, forming scar tissue that physically...
856
01:01Neuroplasticity
444
Neuroplasticity reflects the brain's remarkable capacity to adapt and evolve, responding dynamically to learning, experiences, or injury by reorganizing its neural circuitry. This reorganization involves creating new neural connections and refining old ones through a series of biological processes that contribute to the brain's lifelong development and adaptability.
444